U.S. :
+1-206-701-6702
UK :
+44-020-8133-4027
JAPAN :
+81-50-5539-1737
INDIA :
+91-848-285-0837
Press Release: Companion Animal Vaccine Market to Surpass US$ 4,437.0 Million by 2027
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Veterinary vaccines play a crucial role in ensuring longevity, good health and improving overall productivity of pets, in a cost-effective manner. Veterinary vaccines also play an important role in reducing transmission of various diseases from animals to humans. Companion animal vaccines are parenteral products that are used in prophylactic treatment of various diseases transmitted by animals as well as for treatment of various veterinary diseases.
The companion animal vaccines market is expected to witness significant growth during the forecast period due to increasing pet ownership. For instance, according to the American Pet Products Association's 2017-2018 National Pet Owners Survey, around 89.7 million pets are owned in the U.S. According to the same source, around 63.4 million households own pet dogs and around 42.7 million households own pet cats.
The global companion animal vaccines market value is estimated to be valued at US$ 2,847.7 Mn in 2020 and is expected to increase to US$ 4,437.0 Mn by 2027, witnessing a CAGR of 6.5% during the forecast period.
Figure 1. Global Companion Animal Vaccine Market Value (%) by 2020
Various manufacturers are focusing on mergers and acquisitions, in order to increase their product portfolio and geographical presence in the global companion animal vaccines market. For instance, in 2017, Boehringer Ingelheim acquired Merial, animal health business division of Sanofi. The acquisition helped Boehringer Ingelheim to strengthen its position in the animal healthcare sector.
The rising number of grants for the launch of various anti-cancer therapies for veterinary cancer treatment is expected to be a major factor driving growth of the global companion animal vaccines market during the forecast period. For instance, in 2017, Animal Cancer Foundation (ACF) received a grant of US$ 1 million from the Blue Buffalo Foundation to support an oncology research which would study similarities between naturally occurring cancers in people and pets, and find effective treatment in both species.
The global companion animal vaccines market is expected to witness considerable growth owing to increasing epidemiology of diseases such as melanoma and carcinoma. For instance, According to the study by Cancer News, 2016, grey horses over 15 years of age are more prone to develop melanoma, with an estimated prevalence of 80%. The study also states that squamous cell carcinoma is the second-most common cancer in horses, accounting for 20% of all diagnosed cancer. Moreover, incidence of ovarian cancer is 2.5% to 6% of all equine cancers.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2019 | Market Size in 2019: | US$ 2,847.7 Mn |
| Historical Data for: | 2016 to 2019 | Forecast Period: | 2020 to 2027 |
| Forecast Period 2020 to 2027 CAGR: | 6.5 % | 2027 Value Projection: | US$ 4,437.0 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Elanco Animal Health Incorporated, Boehringer Ingelheim GmbH, Ceva, Merck & Co., Inc., Virbac, Zoetis Inc., HIPRA, Biogénesis Bagó, and Ourofino Animal Health |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Furthermore increasing pet ownership during the forecast period is also expected to drive the market growth .For instance, according to the American Pet Products Association's 2017-2018 National Pet Owners Survey, there are approximately 89.7 million pets owned in the U.S. According to the same source, around 63.4 million households own pet dogs and around 42.7 million households own pet cats.
Global Companion Animal Vaccine Market – Impact of Coronavirus (COVID-19) Pandemic
Supply chain and manufacturing activities in India, Italy, Spain, U.K. and the U.S. have been disrupted due to nationwide lockdowns. Whereas, countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of vaccines. Vaccination is a major requirement to protect companion animals from bacterial or viral infections, which might be delayed due to pandemic.
For instance, CZ Vaccines, a leading biotechnological company and animal vaccine manufacturing, headquartered in Spain, experienced a slow-down in supply chain and manufacturing activities due to COVID19 lockdown.
However, some players in the global companion animal vaccines market reported that their manufacturing and supply processes were operational despite the pandemic. For instance, Elanco Animal Health reported that its manufacturing network remained fully operational. The company is taking extra precautions to protect its team and ensure continuity of supply.
Figure 2. Global Companion Animal Vaccine Market Share (US$ Mn), by Region, 2020
Launch of vaccines for pet animals is a major factor that is driving growth of the North America companion animal vaccines market. For instance, in February 2018, Boehringer Ingelheim and Merial launched the oral vaccine against canine infectious tracheobronchitis caused by Bordetella bronchiseptica in the U.S.
In Europe, manufacturers are focused on development of vaccines for companion animals which is expected to favor growth of the market in this region. Manufacturers are adopting inorganic growth strategies such as acquisitions to increase their presence in the global market. For instance, in 2016, Ceva Sante Animale (Ceva) acquired Hertape Saude Animale Ltd. and Inova Biotecnologia Saude Animale Ltd., the acquisition helpded the company to expand research and development of vaccines and enter the companion animal vaccines market.
Key Players
Major players operating in the global companion animal vaccine market are Elanco Animal Health Incorporated, Boehringer Ingelheim GmbH, Ceva, Merck & Co., Inc., Virbac, Zoetis Inc, HIPRA, Biogénesis Bagó, and Ourofino Animal Health.
Veterinary vaccines play an important role in improving the health of companion animals in a cost effective manner. These vaccines are also important for reducing viral diseases transmitted from animals to animals or animals to humans. The U.S. FDA’s Center for Veterinary Medicine (CVM) approves drugs for companion (pet) animals such as dogs, cats, and horses; and for food-producing animals such as cattle, pigs, and chickens. It conducts research that helps the FDA to ensure safety of animal drugs and food products made from animals.
Moreover, increasing initiatives from regulatory authorities for prevention of diseases such as viral diseases in companion animals are expected to boost the global companion animal market. For instance, according to The American Animal Hospital Association (AAHA) has commissioned a task force of veterinary oncology experts to develop a set of guidelines that will help veterinary teams to work with pet owners for tailored treatment plans that will improve the quality of life of pets with cancer
Market Dynamics
Approval of novel companion animal vaccines and key players focusing on research and development are major factors driving the companion animal vaccine market growth. For instance, in May 2020, MSD Animal Health, a division of Merck & Co., Inc. launched NOBIVAC Myxo-RHD PLUS vaccine to decrease mortality, due to most common viral diseases in rabbits such as myxomatosis and rabbit haemorrhagic disease (RHD).
Moreover, key companies are focusing on mergers and acquisitions to strengthen their position in the companion animal vaccine market which is expected to facilitate the market growth. In July 2019, Elanco Animal Health Incorporated announced the acquisition of Aratana Therapeutics, a veterinary oncology company focused on developing and commercializing innovative therapeutics for dogs and cats, and a developer of the first-of-its-kind canine NSAID for osteoarthritis, Galliprant. Moreover, in 2019, Elanco also signed a development and commercialization agreement with VetDC for Tanovea-CA1.
Increase product launches and product commercialization by government regulatory agencies in companion animal vaccine manufacturing is expected to drive the global companion animal vaccine market growth during the forecast period. For instance, the EU’s Committee for Medicinal Products for Veterinary Use (CVMP) is responsible for veterinary biologic manufacturing and product testing and approval oversight. Additionally. countries within the EU have separate consideration for commercialization of the veterinary vaccines.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
*Browse 35 market data tables and 39 figures on "Global Companion Animal Vaccine Market– Regional forecast to 2027”.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Sales Office (U.S.) : Coherent Market Insights Pvt Ltd, 1001 4th Ave,
#3200 Seattle, WA 98154, U.S.
Asia Pacific Intelligence Center (India) : Coherent Market Insights Pvt Ltd, 203, 2nd Floor,
Bremen Business Center, Aundh, Pune,
Maharashtra 411007, India.
UK :
+44-020-8133-4027
JAPAN :
+81-50-5539-1737
This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection
US :
INDIA :
UK :
JAPAN :
Contact Us
